Last updated: February 24, 2026
What is NDC 42291-0970?
NDC 42291-0970 is the National Drug Code for Cytokine Therapy Drug XYZ (placeholder name for analysis). It is a biologic approved for [specific indications, e.g., treatment of melanoma]. The drug received FDA approval on [approval date, e.g., March 15, 2022]. It belongs to [drug class, e.g., immunomodulators] and is manufactured by [manufacturer name].
Market Overview
The biologic oncology segment has experienced significant growth, driven by advances in immunotherapy and targeted treatments. The demand for cytokine-based therapies has increased as they offer effective options for [specific patient populations or indications].
Market Size and Growth
- The global biologic drugs market was valued at approximately USD 250 billion in 2022.
- The immunotherapy segment, which includes cytokine therapies, accounted for roughly USD 60 billion of this valuation.
- Projected compound annual growth rate (CAGR) for biologics through 2027 is approximately 10% (Mordor Intelligence, 2022).
Key Competitors
| Drug Name |
Indication |
Market Status |
Price Range (per dose/annual) |
| Nivolumab (Opdivo) |
Various cancers, including melanoma |
Established, high sales |
USD 150,000/year |
| Pembrolizumab (Keytruda) |
Multiple indications, aggressive cancers |
Market leader |
USD 165,000/year |
| Interleukin-2 |
Approved for melanoma and renal cell carcinoma |
Generic/old biologic |
USD 75,000–100,000/year |
Price Projections
Current Pricing Landscape
- List price for cytokine therapies ranges from USD 70,000 to USD 200,000 annually per patient.
- Pricing factors include manufacturing complexity, rarity of indication, treatment duration, and competitive landscape.
Short-term Projection (Next 1-2 Years)
- Given the drug's recent approval, initial list prices are likely around USD 100,000–USD 150,000 per patient annually.
- Insurance reimbursement pressures could result in net prices approximately 10-15% lower than list prices.
- Launch strategies emphasizing differentiated efficacy or safety may allow for premium pricing within the range.
Long-term Projection (3-5 Years)
- As biosimilar or generic cytokine options enter the market, prices may decline by 20-30%.
- Market penetration and patient access will influence actual prices, with larger health systems negotiating discounts.
- If the drug proves superior or offers unique benefits, premium pricing could persist, maintaining USD 120,000–USD 180,000 annually.
Factors Influencing Price Trajectory
- Regulatory approvals for additional indications could expand market size and justify higher prices.
- Reimbursement policies in the US, EU, and emerging markets will impact ultimate price realizations.
- Manufacturing costs and supply chain stability influence baseline pricing.
Revenue Potential
Assuming:
- 2023 launch with initial uptake reaching 1,000 patients.
- Year-on-year patient growth of approximately 15% due to increasing indications and expanded access.
- An average price point of USD 125,000 per patient annually.
Expected revenue in the first year:
| Year |
Patients |
Revenue (USD) |
Notes |
| 2023 |
1,000 |
125 million |
Launch year, high uptake |
| 2024 |
1,150 |
143.75 million |
Growth from expanded access |
| 2025 |
1,322 |
165.25 million |
Broadened indications |
Risks and Challenges
- Regulatory hurdles: Additional approvals or label modifications may delay or limit market expansion.
- Competition: Established cytokine therapies and emerging biologics could suppress pricing power.
- Market acceptance: Adoption depends on clinical efficacy, safety profile, and payer reimbursement.
Key Takeaways
- The drug currently resides in an expanding biologic immunotherapy market.
- Initial prices are estimated between USD 100,000 and USD 150,000 annually per patient.
- Long-term prices could decline as biosimilars and generics enter the market, but differentiated benefits might sustain premium pricing.
- Revenue growth hinges on patient uptake, indication expansion, and reimbursement environment.
FAQs
What factors influence the price of cytokine biologics?
Manufacturing complexity, indication rarity, competitive landscape, and reimbursement policies shape prices.
How quickly might biosimilars impact pricing?
Biosimilar approvals could enter the market within 3-5 years of original biologic approval, typically reducing prices by 20-30%.
Are there regional differences in pricing?
Yes. US prices tend to be higher due to different healthcare reimbursement systems. European markets often negotiate lower prices, and emerging markets face further discounts.
What is the typical reimbursement trajectory for new biologics?
Initial reimbursement negotiations are favorable if clinical benefits are clear. Price adjustments often follow as payers and healthcare systems evaluate real-world data.
How does indication expansion affect market size?
New approved indications increase patient populations, leading to higher revenue potential and justification for sustained or higher prices for the original drug.
References
- Mordor Intelligence. (2022). Global Biologics Market - Growth, Trends, and Forecast (2022-2027).
- IQVIA. (2022). Global Oncology Market Insights.
- FDA. (2022). Biologics License Application (BLA) Approvals.
- Evaluate Pharma. (2022). Top Pharma Trends and Forecasts.
